ImmuPharma (LON:IMM) Stock Price Down 9.1% – Here’s What Happened

ImmuPharma plc (LON:IMM) dropped 9.1% on Monday . The company traded as low as GBX 8.33 ($0.11) and last traded at GBX 9.50 ($0.13). Approximately 8,992,357 shares were traded during mid-day trading, an increase of 5% from the average daily volume of 8,566,823 shares. The stock had previously closed at GBX 10.45 ($0.14).

ImmuPharma Trading Down 9.1%

The stock has a 50 day simple moving average of GBX 5.17 and a 200 day simple moving average of GBX 3.54. The firm has a market capitalization of £47.47 million, a PE ratio of -1,067.42 and a beta of 1.53.

ImmuPharma (LON:IMM) last released its quarterly earnings data on Wednesday, August 6th. The company reported GBX (0.38) earnings per share (EPS) for the quarter. ImmuPharma had a net margin of 3,519.56% and a negative return on equity of 131.41%. As a group, equities analysts anticipate that ImmuPharma plc will post -339.0000022 earnings per share for the current year.

About ImmuPharma

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.